Beam Therapeutics Announces New Data from the BEACON Phase 1/2 Clinical Trial of BEAM-101 in Sickle Cell Disease at the American Society of Hematology (ASH) Annual Meeting
All seven patients treated with BEAM-101 achieved hemoglobin F (HbF) induction >…
